ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Minority Interest
ScinoPharm Taiwan Ltd
Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Minority Interest
NT$1.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
64%
|
CAGR 10-Years
25%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Minority Interest
NT$962.7m
|
CAGR 3-Years
67%
|
CAGR 5-Years
59%
|
CAGR 10-Years
N/A
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Minority Interest
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Minority Interest
NT$3.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
You don't have any saved screeners yet